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Abstract: We investigated the effects of a fibrin-hyaluronic acid hydrogel (FBG–HA) and fibroblast
growth factor 18 (FGF-18) for nucleus pulposus (NP) regeneration. Healthy bovine (n = 4) and human
degenerated NP cells (n = 4) were cultured for 14 days in FBG-HA hydrogel with FGF-18 (∆51-mutant
or wild-type) in the culture medium. Gene expression, DNA content, and glycosaminoglycan (GAG)
synthesis were evaluated on day 7 and 14. Additionally, histology was performed. Human NP cells
cultured in FBG-HA hydrogel showed an increase in collagen type II (COL2) and carbonic anhydrase
XII (CA12) gene expression after 14 or 7 days of culture, respectively. GAG release into the conditioned
medium increased over 14 days. Healthy bovine NP cells showed increased gene expression of
ACAN from day 7 to day 14. Wild type FGF-18 up-regulated CA12 gene expression of human NP
cells. Histology revealed an increase of proteoglycan deposition upon FGF-18 stimulation in bovine
but not in human NP cells. The FBG-HA hydrogel had a positive modulatory effect on human
degenerated NP cells. Under the tested conditions, no significant effect of FGF-18 was observed on
cell proliferation or GAG synthesis in human NP cells.
Keywords: fibrin-hyaluronic acid hydrogel; fibroblast growth factor 18; nucleus pulposus cells
1. Introduction
During the early degeneration process of the intervertebral disc (IVD), the nucleus pulposus
(NP) as the inner, gelatinous part of the IVD loses the notochordal cells, which are replaced by more
mature chondrocyte-like NP cells [1]. This mainly leads to a change in the extracellular matrix (ECM),
whereby water-binding proteoglycans (PG) and collagens such as collagen type II are replaced by a
more fibrous, stiff matrix mainly consisting of collagen type I [2]. This naturally degenerative process
is not painful per se, as there are many patients with radiographic signs of IVD degeneration who do
not suffer from back pain [3]. Nevertheless, there is a connection between disc degeneration and low
back pain—the degenerative process causes an inflammatory environment in the IVD [4] and nerve
ingrowth into the NP [5]. This leads to the clinical term degenerative disc disease (DDD). The “painful
disc” or “discogenic pain” is described to be the main cause of low back pain in 26–42% of cases [6,7].
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Besides surgical treatment, there is neither a minimally invasive treatment of discogenic pain, nor a
possibility of drug-induced regeneration of the disc. Many growth factors have been investigated in
pre-clinical studies [8–10]. Despite their promising in vitro results, there are still no clinical uses of
growth factors for disc regeneration [10].
Fibroblast growth factor (FGF)-18 was first described in 1998 [11]. It acts as a signal protein
in many physiological processes including chondrogenesis and skeletal development [12], where it
stimulates anabolic processes in chondrocytes [13]. In the past years, a recombinant form of FGF-18
(rhFGF-18, Sprifermin) has been used as an experimental drug for the treatment of osteoarthritis (OA)
in the knee joint [14–17]. This approach was based on the strong chondrogenic effect of FGF18 on
human articular chondrocytes in vitro. Aside from this, a missense mutation leading to a constantly
active FGF receptor 3 (FGFR3), the authentic receptor for FGF18, was discovered to be the cause of
the genetic short limb dwarfism, achondroplasia (ACH) [18]. Because of the low incidence of OA in
patients with ACH, it was suggested that the ACH mutation may protect against OA [19].
The signaling of all members of the FGF family occurs through the FGF receptors (FGFR). FGFR
are transmembrane receptors, which can be classified into four types—FGFR1–4 [20]. They contain an
extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic domain containing
a split tyrosine kinase (sub)domain [21]. The FGF-18 wild type (WT) binds to its receptors with different
affinities—FGFR3c > 4∆ > 2c > 1c >> 3b [20]. As the binding of FGF-18 to the FGFR3 leads to its
chondrogenesis signaling-cascade [22], we previously developed an FGF-18 mutant (FGF-18 ∆51) to
increase the selectivity of FGF-18 to FGFR3 [23]. To our knowledge, the potential regenerative effect of
FGF-18 on NP cells is still unknown [10].
For an intradiscal growth factor delivery, a hyaluronic acid (HA)-based hydrogel has been
suggested to be an appropriate carrier material. HA is a natural component of the NP ECM, and HA-
based hydrogels with high molecular weight have shown to decrease inflammation in both NP [24–26]
and cartilage tissue [27]. Fibrinogen–HA conjugate (FBG-HA), is water-soluble and polymerizes by
cross-linking upon the addition of thrombin. This injectable viscoelastic hydrogel (RegenoGel) has
already been approved for clinical use by the Israel Ministry of Health for intra-articular application in
osteoarthritic knee joints [28].
Many similarities exist between the NP tissue and articular cartilage, including the hypoxic
environment [29], the ECM composition [30], low cellularity [31], and a similar cell phenotype [32],
suggesting possible similar effects of regenerative factors on chondrocytes and NP cells. Here,
we studied the potential of both FGF-18 (wild type and ∆51 mutant) and the FBG-HA hydrogel for
NP regeneration by analyzing gene expression of NP matrix components and NP cell phenotypic
markers, as well as the effect on ECM production in healthy bovine and mildly degenerated human
NP-derived cells.
2. Results
2.1. Expression of the FGF Receptors 1−4 in Bovine and Human NP Cells
In healthy bovine NP cells, all FGF receptors (FGFR1–4) were expressed on the mRNA level.
Encapsulation in hydrogel showed an upregulation of the FGFR1, -3, and -4 after 14 days of culture
compared to the expression level on day 1. The FGFR4 showed the highest increase of gene expression
over time (p < 0.001 vs. day 1). Additional stimulation with FGF18 ∆51 mutant showed a significant
down-regulation of the FGFR3 after 7 days of culture (p < 0.05 for 10 ng/mL; p < 0.01 for 100 ng/mL)
compared to the control group on day 7. No significant effects on FGFR1, -2, and -4 gene expression
was detected with 10 and 100 ng/mL FGF18 ∆51 compared to the control (Figure 1A).
Human mildly degenerated NP cells showed a different FGFR expression profile compared to
bovine cells. FGFR1 was significantly upregulated by encapsulating cells in hydrogel over 7 days
(p < 0.01 vs. day 1). FGFR3 and -4 were detected on day 1 in all the four donors. After 7 or 14 days of
culture, two donors of Pfirrmann grade 2 and 3 did not express FGFR3 and FGFR4, whereas another
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two donors at Pfirrmann grade 2 maintained comparable gene expression levels of FGFR3 and FGFR4
compared with day 1. These results indicate that human mildly degenerated NP cells can lose the FGF
receptor expression after in vitro three dimensional (3D) culture within FBG-HA hydrogel. FGF-18
WT stimulation did not show any effect on the gene expression level of FGFRs 1−4 compared to the
unstimulated control (Figure 1B).
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FGFR3 and FGFR4 at the mRNA level, indicated as n.d. = not detected), # p < 0.05, ## p < 0.01, ### p < 
0.001 vs. day 1, * p < 0.05, ** p < 0.01. 
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The gene expression of the NP cell markers carbonic anhydrase 12 (CA12) and keratin 19 
(KRT19) in healthy bovine NP cells did not change significantly over 14 days of culture with or 
without FGF-18 ∆51 stimulation (Figure 2A). On the other hand, mildly degenerated human NP cells 
showed a significant increase of CA12 gene expression upon stimulation with 100 ng/mL FGF-18 WT 
on day 7, which indicated a positive modulation of the NP cell phenotype (Figure 2B). KRT19 
expression showed a trend of increase in bovine and human NP cells cultured in FBG-HA hydrogels 
after 7 and 14 days, although this was not significant. 
Figure 1. Relative mRNA expression of fibroblast growth factor (FGF) receptor 1−4 of (A) bovine
(healthy) nucleus pulposus cells and (B) human (mildly degenerated) nucleus pulposus cells
encapsulated in fibrinogen– hyaluronic acid conjugate (FBG-HA) hydrogel and stimulated with
10 or 100 ng/mL FGF-18 (FGF-18 ∆51 for bovine and FGF-18 wild type (WT) for human nucleus
pulposus (NP) cells), after 7 or 14 days of culture. Data were normalized to the expression level of cells
at day 1 in hydrogel culture. n = 4 (in human NP cells, two out of four donors did not show expression
of FGFR3 and FGFR4 at the mRNA level, indicated as n.d. = not detected), # p < 0.05, ## p < 0.01, ###
p < 0.001 vs. day 1, * p < 0.05, ** p < 0.01.
2.2. Expression of NP Cell Markers in Bovine and Human NP Cells
The gene expression of the NP cell markers carbonic anhydrase 12 (CA12) and keratin 19 (KRT19)
in healt y bovine NP cells did not change significantly over 14 days of culture with or without
FGF-18 ∆51 stimulation (Figure 2A). On the other hand, mildly degenerated human NP cells sho ed a
significant increase of CA12 gene expression upon stimulation with 100 ng/mL FGF-18 WT on day 7,
which indicated a positive modulation of the NP cell phenotype (Figure 2B). KRT19 expression showed
a trend of increase in bovine and human NP cells cultured in FBG-HA hydrogels after 7 and 14 days,
although this was not significant.
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Figure 2. Relative mRNA expression of NP cell marker genes carbonic anhydrase 12 (CA12) and
keratin 19 (KRT19) of (A) bovine (healthy) nucleus pulposus cells and (B) human (mildly degenerated)
nucleus pulposus cells encapsulated in FBG-HA hydrogel and stimulated with 10 or 100 ng/mL FGF-18
(FGF-18 ∆51 for bovine and FGF-18 WT for human NP cells), after 7 or 14 days of culture. Data were
normalized to the expression level of cells at day 1 in hydrogel culture. n = 4, # p < 0.05 vs. day 1.
2.3. Gene Expression of IVD Matrix Molecule and Catabolic Markers in Bovine and Human NP Cells
There was no significant change in gene expression of collagen type I (COL1) and collagen type
II (COL2) in healthy bovine cells with or without FGF-18 ∆51. After 14 days of culture, there was a
significant increase in the aggrecan (ACAN) gene expression in FBG-HA hydrogel culture (p < 0.05
day 7 vs. day 14). By adding 10 ng/mL FGF-18 ∆51, this up-regulation effect was significantly
diminished (p < 0.01), but it was still higher than the level on day 1. The catabolic gene marker
matrix metalloproteinase-3 (MMP3) was significantly downregulated (compared to day 1) by adding
10 ng/mL FGF-18 ∆51 (p < 0.05) after 7 days. The catabolic marker a disintegrin and metalloproteinase
with thrombospondin motif 4 (ADAMTS4) was significantly downregulated (compared to day 1)
after 7 days with both tested concentrations of FGF-18 ∆51 (p < 0.01 at 10 ng/mL, and p < 0.001 at
100 ng/mL). ADAMTS5 showed no significant changes in gene expression over 14 days. Aside from
this, no significant changes in ADAMTS5 were seen between the control and the FGF-18 groups
(Figure 3A).
In human NP cells, the COL1 gene expression did not significantly change over time with or
without FGF-18 WT (Figure 3B), whereas COL2 was significantly upregulated within all groups except
for 10 ng/mL FGF-18 WT compared to day 1. ACAN expression level showed a donor-dependent
increase after 14 days of culture in FBG-HA hydrogel, although it was not significant (Figure 3B).
FGF-18 WT did not show a significant effect on the expression of COL2 or ACAN in human NP cells.
The catabolic marker MMP3 was insignificantly downregulated by adding FGF-18 WT. Compared
with healthy bovine NP cells, ADAMTS4 showed a contrary expression pattern. All tested groups
showed a significant upregulation of ADAMTS4 after 7 and 14 days. No significant differences of
ADAMTS5 gene expression could be detected after 7 and 14 days of culture (Figure 3B).
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Figure 3. Relative mRNA expression of collagen type I (COL1), collagen type II (COL2), aggrecan
(ACAN), and the catabolic markers matrix metalloproteinase-3 (M P3) and a disintegrin and
metalloproteinase with thrombospondin motif 4 and 5 (ADAMTS4 and ADAMTS5) of (A) bovine
(healthy) nucleus pulposus cells and (B) human (mildly degenerated) nucleus pulposus cells
encapsulated in FBG- A hydrogel and stimulated with 10 or 100 ng/mL FGF-18, after 7 or 14
days of culture. Data were normalized to the expression level of cells at day 1 in hydrogel culture.
n = 4, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. day 1, * p < 0.05, ** p < 0.01.
2.4. Proliferation and Matrix Protein Synthesis of Bovine and Human NP Cells
DNA content was determined as an indicator of cell proliferation. Over 14 days, bovine NP
cells showed a decrease in measured DNA content, which was not influenced by FGF-18 (Figure 4A).
Conversely, the DNA content in human NP cells remained constant, and the addition of FGF-18 did
not induce significant changes in DNA content (Figure 4B).
The glycosaminoglycan (GAG) content in each hydrogel with encapsulated cells was normalized
to its DNA content (GAG/DNA, Figure 4C,D). The GAG release into the conditioned medium is shown
in Figure 4E,F. The GAG production from bovine healthy NP cells was approximately 10-fold higher
compared with the human mildly degenerated NP cells during the 14-day culture period. In bovine
NP cells, the GAG/DNA value in the control group (unstimulated) showed a trend to increase over
time (Figure 4C), whereas the GAG content in medium (GAG accumulation over 7 and 14 days)
showed no significant changes after 14 days, with or without FGF-18 stimulation (Figure 4E). In mildly
degenerated human NP cells, there were no significant differences in GAG/DNA values in hydrogels
(Figure 4D). The GAG content in the culture medium significantly increased over time, but did not
differ between groups with or without FGF-18 WT (Figure 4F; 0 and 10 ng/mL p < 0.001; 100 ng/mL
p < 0.01).
Int. J. Mol. Sci. 2019, 20, 5036 6 of 16
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 16 
 
 
Figure 4. DNA (A,B), glycosaminoglycan (GAG)/DNA in hydrogel (C,D), and GAG content in 
medium (E,F) for healthy bovine nucleus pulposus cells (A,C,E) and mildly degenerated human 
nucleus pulposus cells (B,D,F) encapsulated in FBG-HA hydrogel and stimulated with 10 or 100 
ng/mL FGF-18 after 7 or 14 days of culture. n = 4, ** p < 0.01, *** p < 0.001. 
2.5. Histology Staining 
Images of Safranin O/Fast Green-stained transverse sections of encapsulated NP cells in 
hydrogel for 14 days are shown in Figures 5 and 6. Healthy bovine NP cells showed intense purple 
staining at the outer layer of the hydrogel, which indicated proteoglycan accumulation. An increased 
proteoglycan staining both in terms of staining intensity and size of the stained area was observed 
when incubated with 10 or 100 ng/mL FGF-18 (Figure 5). This was further confirmed by aggrecan 
immunohistochemistry staining in samples with bovine NP cells (Figure 7). Human mildly 
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Figure 4. DNA ( ,B), glycosaminoglycan (GAG)/DNA in hydrogel (C,D), and GAG content in medium
(E,F) for healthy bovine nucleus pulposus cells (A,C,E) and mildly degenerated human nucleus
pulposus cells (B,D,F) encapsulated in FBG-HA hydrogel and stimulated with 10 or 100 ng/mL FGF-18
after 7 or 14 days of culture. n = 4, ** p < 0.01, *** p < 0.001.
2.5. Histology Staining
Images of Safranin O/Fast Green-stained transverse sections of encapsulated NP cells in hydrogel
for 14 days are shown in Figures 5 and 6. Healthy bovine NP cells showed intense purple staining at the
outer layer of the hydrogel, which indicated proteoglycan accumulation. An increased proteoglycan
staining both in terms of staining intensity and size of the stained area was observed when incubated
with 10 or 100 ng/mL FGF-18 (Figure 5). This was further confirmed by aggrecan immunohistochemistry
staining in samples with bovine NP cells (Figure 7). Human mildly degenerated NP cells showed no
difference in staining after 14 days in the FGF-18 treated group compared to the control. Consistent with
the biochemical analysis, we did not detect any effect on proteoglycan staining by FGF-18 stimulation
after 14 days, although hydrogels of the FGF-18 100 ng/mL group showed a slight increase in size and
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collagen staining intensity of the hydrogel (Figure 6). Collagen type II immunohistochemistry staining
was performed in samples with human NP cells, which showed no difference in the staining intensity
among the three groups (Figure 8).
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3. Discussion
Various bioactive growth factors, as well as polymer-based hydrogels have been tested as
non-invasive injectable treatments for IVD regeneration because of their c pacity to support disc cell
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growth and metabolism. To our knowledge, this is the first study that has investigated the effect of
FGF-18 on bovine and human NP cells.
FBG-HA hydrogel showed a translational potential as indicated by its positive modulatory
effect on human mildly degenerated NP cells. FBG-HA conjugate-based hydrogels were found
to support the survival and differentiation of bovine NP cells [33] and human chondrocytes [34].
In the current study, the FBG-HA hydrogel, which supplied a biomimetic ECM microenvironment,
was used to encapsulate bovine and human NP cells for in vitro 3D culture studies. The hydrogel
could maintain cell survival of human NP cells, as indicated by steady DNA content over 14 days of
culture, whereas a decrease in DNA content was noticed in healthy bovine cell samples over time.
Healthy bovine cells have a higher metabolic activity compared with degenerated human NP cells.
Furthermore, it is known that fibrin degrades over prolonged cultures [35]. In contrast, FBG-HA
hydrogel showed a potential regenerative effect on mildly degenerated human NP cells, as indicated
by upregulation of COL2 gene expression and increased GAG release into the culture medium over 14
days of culture (Figures 3B and 4F). The NP-specific cell phenotype markers CA12 [36] and KRT19 [37]
showed a steady or slightly increased level in healthy bovine and mildly degenerated human NP cells,
respectively, after 14 days culture in FBG-HA hydrogel (Figure 2A,B). This suggested that the specific
cell environment given by the hydrogel could partially retain or regain the healthy NP phenotype,
as it has been shown in former in vitro studies [24,33,38,39]. In cells derived from young and healthy
animals, the NP GAG synthesis level was 10-fold higher compared with mildly degenerated human NP
cells (Figure 4C–F). Upregulation of MMP and ADAMTS expression is implicated in IVD extracellular
matrix degradation, leading to the development of IVD degeneration [40]. On the other hand, a high
aggrecanase activity was observed in human NP tissue until the age of young juvenile, which may be
related to the development or growth of tissue [41]. Bovine NP cells cultured in FBG-HA hydrogel did
not show any significant change in MMP3, ADAMTS4, or ADAMTS5 gene expression after 14 days of
culture. On the other hand, the human NP cells showed an upregulation of ADAMTS4 gene expression
after 3D in vitro culture, which may indicate a degeneration or self-remodeling effect. Overall, these
results indicated a difference in the behavior of bovine healthy NP cells and human mildly degenerated
NP cells cultured in the same microenvironment. The present data indicate no difference between
traumatic and degenerative human NP samples, which can be attributed to the equal degeneration
grade. Nonetheless, because of our small sample size, we cannot make any definitive conclusions
about differences between traumatic and degenerative NP.
In the performed in vitro studies, we could not observe a pronounced effect of FGF-18 for NP
cells. Characterization of the FGF receptor expression on mRNA level showed that healthy bovine
NP cells expressed FGFR3 receptors, which is congruent with former research work [42]. FGFR3 is
the major signal transducer of FGF-18 [12,42]. We, therefore, tested a mutant of FGF-18 (FGF-18 ∆51)
that has increased affinity to FGFR3 [23] for the stimulation of bovine NP cells. To our knowledge,
no studies have been conducted so far on the expression of different FGFRs in bovine or human NP
cells, seen in contrast to articular chondrocytes, which are relatively well-characterized for their FGFR
expression [43]. FGFR3 expression in degenerated human NP cells was found to be highly variable and
donor-dependent (independent from the grade of degeneration), whereby FGFR3 was not detected in
2 out of 4 donors after 7 or 14 days of culture. Therefore, FGF-18 wild type was used in the stimulation
experiments on human NP cells. Dailey and colleagues stated that the activation of FGFR could induce
different responses in different cell types, which might be caused by the ability of the receptors to elicit
different signals (e.g., proliferation, differentiation, or apoptosis, etc.) by engaging the appropriate
transducing molecule [44]. This might explain the regenerative effect of FGF-18 on human articular
OA cartilage but not on human NP. The effect of the regulation of receptor expression in relation to
their individual FGF-18 binding affinity needs further investigation.
FGF-18 did not show a significant effect on marker genes for regeneration, cell proliferation,
or GAG synthesis in human or bovine NP cells. GAG accumulation after stimulation with 10 and
100 ng/mL FGF-18 in the periphery of bovine NP cell samples was observed after 14 days of culture,
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but not in human NP cell samples. This result could be due to the fact that the bovine NP cells were
younger and metabolically more active compared with the mildly degenerated human NP cells [45].
Moreover, FGFR3 showed a higher gene expression in bovine NP cells compared to the degenerated
human NP cells. The concentration of FGF-18 used in the current study (10 and 100 ng/mL) was
comparable to other studies done with different FGFs on nucleus pulposus cells [42] and cartilage [46],
while a direct conjugation to the FBG-HA hydrogel might enhance the potential regenerative effect of
FGF-18 by controlled slow release. Further characterization of the FGFR protein expression on the
cell surface would bring forth insightful information for the application of FGF-18 as a regenerative
therapy. More pronounced matrix synthesis in mildly degenerated human NP cells might be observed
in longer-term studies.
4. Materials and Methods
4.1. Materials and Reagents
An FBG-HA conjugate hydrogel (RegenoGel, available online: https://regenogel.co.il/, accessed on
24 October 2018) [33,47] was synthesized at ProCore Biomed Ltd. (Nes Ziona, IL). The conjugate was
composed of FBG and HA in a 3.2:1 ratio, with a final concentration of 6.25 mg/mL FBG and 1.95 mg/mL
HA. In comparison to hydrogels prepared from FBG alone or in a mixture of FBG and HA, FBG-HA
conjugate hydrogels showed enhanced stability and mechanical properties, including reduced loss of
water and shrinkage over time, as well as more pronounced viscoelastic properties [33,47].
FGF-18 mutant (FGF-18 ∆51) was provided by ProCore Bio-med Inc. (Nes Ziona, IL) and was used
for stimulation of bovine NP cells, which were shown to express the FGFR3 gene. Because expression
of FGFR3 could not be detected in all the donors of mildly degenerated human NP cells, the FGF-18
wild type was used for all experiments with human NP cells (FGF-18, human recombinant, cat. # 4082,
BioVision, Inc. Milpitas, CA, USA). Both types of FGF-18 were reconstituted in phosphate-buffered
saline (PBS) at a concentration of 10 µg/mL, and were further diluted with culture medium in the cell
culture experiment. Heparin (Merck KGaA, Darmstadt, Germany) was added to the culture medium
at a concentration of 1 µg/mL to activate the mitogenic activity of FGF-18 [12].
4.2. Methods
4.2.1. Cell Isolation and In Vitro Culture in FBG-HA Hydrogel
Bovine NP cells were isolated from 8 to 12 months old caudal IVD, as described previously [33].
Human NP tissue was harvested, with ethical approval and the written consent of patients (ethical
committee of the canton of Bern, Switzerland) with traumatically injured or degenerative IVDs, which
were all classified as mildly degenerated (Pfirrmann grade 2–3, 30–55 years) [48]. Intervertebral
disc degeneration is a natural process of aging, beginning as early as the age of 20 years old [49].
The traumatic samples collected in clinics are often mildly degenerated (i.e., Pfirrmann grade 2–3)
and are comparable to degenerative IVD samples. Therefore, calf NP cells at the age of 8–12 months
were used as healthy control. The collected human NP tissue was incubated with red blood cell
lysis buffer for 5 min on a shaker and washed with PBS. The chopped tissue was then enzymatically
digested with 0.2% w/v pronase in alpha minimum essential medium (αMEM) for 1 h, followed by
65 U/mL collagenase type II in αMEM/10% fetal bovine serum (FBS) for 12–14 h at 37 ◦C. The single-cell
suspension obtained by filtering through a 100 µm cell strainer was seeded at a concentration of
10,000 cells/cm2 and expanded with αMEM/10% FBS under 2% O2. Expanded NP cells, bovine or
human (passage 1–2), were encapsulated within FBG-HA hydrogel at a concentration of 6× 105 cells/gel
for healthy bovine and 2 × 105 cells/gel for mildly degenerated human NP cells. The gel was prepared
by mixing 150 µL of FBG-HA conjugate solution containing NP cells with 10 µL of thrombin at room
temperature, followed by a 30 min incubation at 37 ◦C to allow solidification. Cell–gel constructs
were cultured in Dulbecco’s modified Eagle’s medium (DMEM, with 4.5 g/L glucose) with 2% FBS,
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100 U/mL penicillin, 100 mg/mL streptomycin (1% Pen/Step) (all from Gibco, LifeTechnologies Limited,
Paisley, UK), 50 mg/mL L-ascorbic acid 2-phosphate (Merck KGaA, Darmstadt, Germany), 1% ITS
Premix (Discovery Labware, Aldrich, St. Louis, MO), and 1 µg/mL heparin (180 IU/mL, Merck KGaA,
Darmstadt, Germany) for 7 or 14 days. The culture medium was changed every 2–3 days. FGF-18 ∆51
or rhFGF-18 was added to the culture medium at a concentration of 10 or 100 ng/mL.
4.2.2. Biochemical Analysis
On day 7 and 14, cell–gel constructs were digested with 0.5 mg/mL proteinase K at 56 ◦C
overnight. The GAG content in the hydrogels was measured using the 1,9-dimethylmethylene blue
dye (DMMB) method [50] and was normalized to the DNA content in the respective samples. GAG
content in hydrogels without cells on day 0 was subtracted from all samples. The DNA content
in the hydrogels was measured with PicoGreen (Invitrogen, Eugene, OR, USA) according to the
manufacturer’s instructions. The conditioned medium was collected at every medium change, and the
GAG content was determined after 7 and 14 days in the pooled medium.
4.2.3. Gene Expression Analysis
Total RNA was extracted from cell–gel constructs after 1, 7, and 14 days of culture. First, the gels
were homogenized with TRI Reagent (Molecular Research Center MRC, cat. # TR-118, Cincinnati,
OH) supplemented with 5 µL of Polyacryl Carrier (Molecular Research Center MRC, cat. # PC-152,
Cincinnati, OH) in a tissue lyser (Qiagen, Hilden, Germany). The isolation was done by using
a modification of the TRI Reagent procedure for the isolation of RNA from polysaccharide- and
proteoglycan-rich sources. Reverse transcription was carried out with TaqMan Reverse Transcription
Reagents (all from Applied Biosystems, Foster City, CA, USA) and 0.5 µg of total RNA. Real-time
PCR was performed for collagen type I (COL1), collagen type II (COL2), aggrecan (ACAN), matrix
metalloproteinase-3 (MMP3), a disintegrin and metalloproteinase with thrombospondin motifs 4 and
5 (ADAMTS4 and -5), carbonic anhydrase XII (CA12), keratin 19 (KRT19), and FGF receptors 1–4
(Table 1) using TaqMan Universal Master Mix (Applied Biosystems, cat. # 4324018, Carlsbad, CA).
QuantStudio6 Flex Instrument and software (Applied Biosystems) were used for qPCR. Ribosomal
protein lateral stalk subunit P0 (RPLP0) was used as the endogenous control. The comparative Ct
method was performed for the relative quantification of target mRNA.
Table 1. Oligonucleotide primers and probes (bovine and human) used for qRT-PCR. Primers
and probes with the sequence shown were custom-designed; primers and probes with the catalog
number were from Applied Biosystems. fw: Forward, rev: Reverse, FAM: Carboxyfluorescein,
TAMRA: Tetramethylrhodamine.
Gene Primer/Probe Type Sequence
bCOL1
Primer fw (5′–3′) TGC AGT AAC TTC GTG CCT AGC A
Primer rev (5′–3′) CGC GTG GTC CTC TAT CTC CA
Probe (5′FAM/3′TAMRA) CAT GCC AAT CCT TAC AAG AGG CAA CTG C
bCOL2
Primer fw (5′–3′) AAG AAA CAC ATC TGG TTT GGA GAA A
Primer rev (5′–3′) TGG GAG CCA GGT TGT CAT C
Probe (5′FAM/3′TAMRA) CAA CGG TGG CTT CCA CTT CAG CTA TGG
bACAN
Primer fw (5′–3′) CCA ACG AAA CCT ATG ACG TGT ACT
Primer rev (5′–3′) GCA CTC GTT GGC TGC CTC
Probe (5′FAM/3′TAMRA) ATG TTG CAT AGA AGA CCT CGC CCT CCA T
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Table 1. Cont.
Gene Primer/Probe Type Sequence
bMMP3
Primer fw (5′–3′) GGC TGC AAG GGA CAA GGA A
Primer rev (5′–3′) CAA ACT GTT TCG TAT CCT TTG CAA
Probe (5′FAM/3′TAMRA) CAC CAT GGA GCT TGT TCA GCA ATA TCT AGA AAA C
bADAMTS4
Primer fw (5′–3′) CCC CAT GTG CAA CGT CAA G
Primer rev (5′–3′) AGT CTC CAC AAA TCT GCT CAG TGA
Probe (5′FAM/3′TAMRA) AGC CCC CGA AGG GCT AAG CGC
bADAMTS5
Primer fw (5′–3′) GAT GGT CAC GGT AAC TGT TTG CT
Primer rev (5′–3′) GCC GGG ACA CAC CGA GTA C
Probe (5′FAM/3′TAMRA) AGG CCA GAC CTA CGA TGC CAG CC
bCA12
Primer fw (5′–3′) CTG CCA GTC CGC AAT TTG T
Primer rev (5′–3′) CCC CGG ACC TGC ATG TC
Probe (5′FAM/3′TAMRA) CCA CTC AGT GAA GGT GAA ACT GCC CA
bKRT19 Bt03219428_m1
bFGFR1 Bt03258913_m1
bFGFR2 Bt03649230_m1
bFGFR3 Bt03259318_m1
bFGFR4 Bt04292959_m1
bRPLP0 Bt03218086_m1
hCOL1
Primer fw (5′–3′) CCC TGG AAA GAA TGG AGA TGA T
Primer rev (5′–3′) ACT GAA ACC TCT GTG TCC CTT CA
Probe (5′FAM/3′TAMRA) CGG GCA ATC CTC GAG CAC CCT
hCOL2
Primer fw (5′–3′) GGC AAT AGC AGG TTC ACG TAC A
Primer rev (5′–3′) GAT AAC AGT CTT GCC CCA CTT ACC
Probe (5′FAM/3′TAMRA) CCT GAA GGA TGG CTG CAC GAA ACA TAC
hACAN
Primer fw (5′–3′) AGT CCT CAA GCC TCC TGT ACT CA
Primer rev (5′–3′) CGG GAA GTG GCG GTA ACA
Probe (5′FAM/3′TAMRA) CCG GAA TGG AAA CGT GAA TCA GAA TCA ACT
hMMP3 Hs00968305_m1
hADAMTS4 Hs00192708_m1
hADAMTS5 Hs01095518_m1
hKRT19 Hs00761767_s1
hFGFR1 Hs00241111_m1
hFGFR2 Hs01552918_m1
hFGFR3 Hs00179829_m1
hFGFR4 Hs01106910_g1
hRPLP0
Primer fw (5′–3′) TGG GCA AGA ACA CCA TGA TG
Primer rev (5′–3′) CGG ATA TGA GGC AGC AGT TTC
Probe (5′FAM/3′TAMRA) AGG GCA CCT GGA AAA CAA CCC AGC
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4.2.4. Safranin O/Fast Green Staining and Immunohistochemistry
After 14 days of culture with or without FGF-18, FBG-HA hydrogel containing bovine or human
NP cells were fixed in 70% methanol or 4% formalin, respectively, and transferred into PBS with 5%
sucrose at 4 ◦C overnight before cryosectioning. Transverse cryosections were cut at a thickness of
8 µm through the central area of the hydrogel. Sections were stained with 0.1% Safranin O and 0.02%
Fast Green to reveal proteoglycan and collagen deposition, respectively, and were then counterstained
with Weigert’s Haematoxylin to reveal cell distribution.
Aggrecan immunohistochemistry staining was performed in samples with bovine NP cells [51].
After reduction and alkylation, sections were pre-treated with 0.025 U/mL chondroitinase ABC
(Sigma-Aldrich Co., St. Louis, MO, USA) at 37 ◦C for 30 min, probed with aggrecan antibody (12/21/1-C-6,
5 µg/mL IgG, Developmental Studies Hybridoma Bank, University of Iowa) at 4 ◦C overnight, followed
by incubation with a biotinylated horse anti-mouse secondary antibody, avidin-biotin-peroxidase
(Vectastain Elite ABC kit, Vector Laboratories, city, state abbreviation if available, Burlingame, CA,
USA), and ImmPACT®DAB Peroxidase (HRP) Substrate (Vector Laboratories). Collagen type II
immunohistochemistry staining was performed in samples with human NP cells. Sections were
pre-treated with 25 mg/mL hyaluronidase (Sigma-Aldrich Co.) and 0.25 U/mL chondroitinase ABC at
37 ◦C for 30 min, probed with collagen type II antibody (CIICI, 1 µg/mL IgG, Developmental Studies
Hybridoma Bank, University of Iowa) at 4 ◦C overnight, followed by incubation with a biotinylated
horse anti-mouse secondary antibody, avidin-biotin-peroxidase, and DAB. Negative control sections
were incubated without the primary antibody. Sections were imaged in transmitted light using a Bx63
microscope (Olympus, Tokyo, Japan).
4.2.5. Statistical Analysis
Graph Pad Prism V8 software (GraphPad Software, San Diego, CA, USA) was used for statistical
analysis. One sample Kolmogorov–Smirnov test was used to define whether the data were normally
distributed (normal distribution at p > 0.1). For data that were normally distributed, one-way
ANOVA with Tukey’s post hoc test was used to determine differences among three or more groups,
and unpaired t-test was used to determine differences between two groups. For data that were not
normally distributed, Kruskal–Wallis test was used to determine differences among three or more
groups, and Mann–Whitney U-test was used to determine differences between two groups. A p-value
< 0.05 was considered statistically significant, and a p-value < 0.1 was considered to indicate a trend.
Two technical replicates were performed in biochemical analyses, and three technical replicates were
done for qPCR. Four different donors were used for bovine and human NP cells.
5. Conclusions
In conclusion, our results showed that the FBG-HA hydrogel supported the survival and positively
modulated the phenotype of mildly degenerated human NP-derived cells within a biocompatible
biomimetic 3D environment. The FBG-HA hydrogel might be a promising treatment option for NP
regeneration and could serve as a carrier for a variety of growth factors and cells. Further preclinical
studies are required to determine their therapeutic potential. By adding FGF-18, we could not see a
significant effect on bovine and human NP cells at the tested experimental conditions.
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